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Cannabidiol enhancement of exposure
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with phobias: study protocol of a
randomized controlled trial
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Abstract
Background: Phobic anxiety disorders are among the most prevalent psychiatric disorders and are burdensome in
terms of loss of quality of life and work productivity. Evidence-based treatments are relatively successful in the
majority of patients, especially exposure therapy. However, a substantial subset of patients fails to achieve or stay in
remission. Preclinical and genetic research have yielded evidence that the cannabinoid system is involved in the
extinction of fear, presumed to underlie the beneficial effects of exposure therapy in phobic disorders. A
cannabinoid constituent that may enhance endocannabinoid signaling is cannabidiol (CBD), a non-psychoactive
component of cannabis. Hence, the addition of CBD to exposure therapy is expected to strengthen effects of
treatment. To determine the added benefit of CBD on exposure therapy, we conduct a randomized controlled trial,
in which patients in whom previous treatment as usual has not yielded sufficient response receive either CBD or
placebo preceding 8 exposure sessions in a double-blind fashion. A subsidiary aim is to explore which
(combination of) clinical, behavioral and genetic profiles of patients are related to treatment response.
Methods/design: This is an 8-week multicenter, randomized, double-blind, placebo-controlled trial. Seventy-two
patients with social phobia or panic disorder with agoraphobia with incomplete response to earlier treatment will
be included from outpatient clinics in the Netherlands. Patients are randomized to augmentation of exposure
therapy with 300 mg CBD or placebo. The study medication is administered orally, 2 h preceding each of the eight
90 min exposure sessions. Measurements will take place at baseline, first administration of medication, every session,
mid-treatment, last administration of medication, post-treatment and at 3 and 6 months’ follow-up. The primary
outcome measure is the score on the Fear Questionnaire (FQ). In addition, determinants of the expected treatment
enhancing effect of CBD will be explored.
Discussion: This is the first trial to investigate whether the addition of CBD to exposure therapy is effective in
reducing phobic symptoms in treatment refractory patients with social phobia or panic disorder with agoraphobia.
Trial registration: Netherlands Trial Register NTR5100. Registered 13 March 2015. Protocol version: issue date 17
Jan 2018, protocol amendment number 7.
Keywords: Anxiety disorders, Panic disorder with agoraphobia, Social phobia, Cannabidiol, Exposure therapy,
Randomized controlled trial, Cannabinoid system, Treatment resistance
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Background
Phobic disorders (e.g. social anxiety disorder, panic dis-
order with agoraphobia) are among the most prevalent
disorders according to the World Health Organization’s
World Mental Health Survey Initiative [1]. These and
other anxiety disorders have major impact on health, in-
dividual suffering and societal costs [2]. The estimated
societal costs in Europe as a result of anxiety disorders
were 74.4 billion Euros in 2010, affecting more than 69
million Europeans [3]. Anxiety disorders often co-occur
with other mental health disorders [4, 5], and are associ-
ated with an increased risk of suicide [6]. Spontaneous
recovery from these disorders is uncommon; if left un-
treated, phobias typically follow a chronic course, with
low remission and high relapse rates [7].
The current evidence-based treatment entails exposure
with response prevention therapy, either alone or in com-
bination with serotonin reuptake inhibitors (SSRIs). Ex-
posure therapy is relatively successful, with improvement
in up to 60% of patients. However, only 30 to 50% of pho-
bic patients achieves full remission [8]. Likewise, treat-
ment with SSRIs is relatively effective, however, many
patients experience relapse after discontinuing SSRI treat-
ment [9, 10], while the effects of successful exposure treat-
ment seem to be more sustainable [11]. Considering the
high prevalence of anxiety disorders and the large number
of patients for whom the anxiety symptoms remain refrac-
tory after (repeated) gold-standard treatments, new ap-
proaches to the treatment of anxiety are urgently needed
[12, 13]. Preclinical as well as clinical studies have pointed
to the relevance of utilizing fear learning paradigms for a
deeper understanding of the neurocircuitry and neuro-
chemistry of the fear system involved in anxiety disorders
[14]. Specifically, patients with anxiety disorders show
stronger fear responses during extinction than comparison
subjects [15], and poor fear extinction is predictive of poor
outcome in exposure therapy [16].
A potential novel target for the facilitation of fear ex-
tinction has been derived from preclinical research. The
crucial involvement of the cannabinoid system in fear
extinction was first shown by Marsicano et al. [17]. The
results show that (genetic or pharmacological) blockage
of transmission at the cannabinoid receptor 1 (CB1) in-
hibits extinction of fear in mice. This is not surprising
given the fact the CB1 receptors are richly expressed in
memory-related brain areas such as hippocampus and
prefrontal cortex, and as such can modulate (fear) mem-
ory [18]. In the last 15 years many studies have extended
this finding using both animal and human subjects (for
reviews see [12] or [19]). Animal research has shown
that facilitation of the endocannabinoid system (ECS)
enhances extinction, whereas blocking or deletion of
CB1 receptors impairs extinction. In healthy human sub-
jects we have demonstrated that genetic variation in a
CB1 polymorphism significantly affected extinction
learning [20]. Furthermore, the administration of canna-
binoids in humans has shown to strengthen extinction
and protect against reinstatement of fear [21–23]. In
summary, previous research clearly points to the ECS as
a promising candidate for extinction enhancement. Until
now, studies in humans have mainly investigated the ef-
fects of delta-9-tetrahydrocannabinol (THC), which has
been shown to decrease physiological measures of fear
during extinction [24] and recall [21]. However, THC is
not suitable for phobic patients given the diversity of
psychoactive effects caused by THC, among which the
high that recreational users of cannabis seek.
In the meantime, studies have demonstrated the poten-
tial benefit of another important ingredient of cannabis:
cannabidiol (CBD, for a review see [25]). CBD interacts
with several receptors in the brain including cannabinoid
receptors 1 and 2, transient receptor potential vanilloid
type 1 (TRVP1) and serotonin 1A (5-HT1A) receptor, and
inhibits or in other ways negatively affects the function of
the enzyme that degrades endogenously released canna-
binoid neurotransmitters (fatty acid amine hydrolase;
FAAH [26]). In line with FAAH’s function in degrading
anandamide [27], inhibition of FAAH has been shown to
increase levels of anandamide. Preclinical research indi-
cates that CBD enhances fear extinction and reconsolida-
tion, and co-administrating CB1 antagonists block such
effects suggesting that they are exerted via modulation of
the ECS [28, 29]. Extinction of conditioned fear is pro-
posed to underlie the effect of exposure therapy [14].
Hence, the finding that CBD specifically affects (the con-
solidation of) extinction suggests a potential use of CBD
in augmenting the effect of exposure therapy. This leads
to the hypothesis that administration of CBD during ses-
sions of exposure therapy is expected to specifically en-
hance the extinction of pathological fears. The advantage
of this application is that CBD needs to be administered
occasionally, i.e. preceding exposure sessions only.
We aim to take this previous research to the next level
by conducting the first randomized controlled trial with
CBD versus 7, administered in a double-blind fashion,
for the augmentation of exposure treatment in patients
with social phobia or panic disorder with agoraphobia.
Also, we aim to specifically target patients who have
already received one of the gold-standard treatments
without responding sufficiently or having relapsed, be-
cause this group needs additional approaches most.
The main study aim is to test whether administration of
CBD as an augmentation step in exposure therapy can
strengthen treatment outcome in patients with phobic dis-
orders who have previously failed to respond satisfactorily
to evidence-based treatment. Clinical measurements are
used to investigate whether the effect of CBD on exposure
is quicker, stronger, or longer-lasting than regular exposure
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therapy only. Additionally, there are various exploratory
subsidiary aims in this study. First, a fear conditioning and
extinction task is applied at baseline. This task has shown
enhanced fear responses in patients with anxiety disorders
as opposed to healthy comparison subjects [30]. This task
also revealed different extinction trajectories, with patients
being overrepresented in a poor extinction profile [16].
These profiles have also shown to be sensitive to differences
between patients who will benefit from exposure treatment
and those who will not. A re-extinction assessment is done
after the first medication administration. The aim of this
task is to explore a) whether patients with a specific profile
can particularly benefit from CBD augmentation during ex-
posure, and b) the acute effects of CBD intake on fear ex-
tinction. Second, we aim to explore the interactions
between specific genetic variation and CBD administration
on treatment effect. We are particularly interested in study-
ing whether variants within the cannabinoid receptor 1
gene are involved in a differential response to CBD aug-
mented exposure therapy, including rs2180619 identified in
our previous study in healthy individuals associated with
impaired spontaneous extinction of conditioned fear [20].
Additionally, impact of genetic polymorphisms within the
FAAH gene [31] and genetic polymorphisms identified as
being related to treatment response in anxiety disorders
[32] will be explored. Similarly, clinical predictors of treat-
ment response will be assessed to determine which sort of
patients might benefit most from this augmented treat-
ment. Lastly, we aim to assess cost-effectiveness of CBD en-
hancement of exposure treatment.
Methods
Study design
The study encompasses a multi-site randomized,
double-blind, placebo-controlled fixed dose clinical trial
for patients with treatment resistant social phobia or
panic disorder with agoraphobia. Either placebo (N = 36)
or 300 mg cannabidiol (N = 36) will be administered 8
times as an adjunct to 8 weekly 90 min sessions consist-
ing of standardized exposure therapy. The study has
been approved by the Medical Ethics Committee of the
University Medical Centre Utrecht. Written informed
consent will be obtained from all participants. The en-
rollment of the first participant was on 15 February
2016, recruitment is ongoing at the time of submission.
Figure 1 displays a flowchart of the study.
Participants
Inclusion criteria
 Adult patients between 18 and 65 years with a
phobic disorder (social phobia or panic disorder
with agoraphobia), diagnosed with the Structured
Clinical Interview on DSM-IV disorders
(SCID; [33])
 At least one attempt to treat the disorder, according
to guidelines, either by means of psychotherapy or
with the use of serotonergic antidepressants, has
induced insufficient clinically relevant response
during or after treatment
Fig. 1 Flowchart of the study design. Data is collected both during T0-T6 measurements and therapy sessions, see Table 1 for a complete overview
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Exclusion criteria
 Co-morbid psychiatric disorders, i.e. current severe
major depressive or bipolar disorder, psychosis,
dependence on alcohol and drugs, as determined by
the SCID
 Mental deficiency (IQ < 80, as determined by the
Nederlandse Leestest voor Volwassenen (NLV; [34]))
 Autism traits (AQ > 32, as determined by the
Autism Spectrum Quotient (AQ; [35]))
 Inadequate proficiency in Dutch, both verbal and
written
 (A history of ) epilepsy, brain damage, cardiac, renal
or liver abnormalities
 History of allergies to medication (adverse reactions
or rash)
 Use of antipsychotic medication
 Regular daytime use of benzodiazepines, since use
concomitant to exposure has been shown to hamper
the treatment effect [36]
 Changes in dosing regimen of serotonergic
antidepressants shorter than 4 weeks prior to study
entry (i.e. use of serotonergic antidepressants at a
stable regimen throughout the study is permitted)
 Use of recreational drugs (among others THC, XTC,
cocaine) from 2months preceding study entry
 Pregnancy or breastfeeding
Sample size
The CBD and placebo groups will each include 36 pa-
tients. The sample size is aimed at detection of a
Cohen’s D effect size of 0.6, based on effect sizes found
in previous published studies on the augmentation of ex-
posure with d-cycloserine [37]. This sample size has
been calculated using G*power version 3.0.10 [38], with
a repeated measures design for two groups with two
measurements, an envisioned effect size of 0.6 Cohen’s
D, error probability of 0.05, power of 0.8 and correlation
among repeated measurements of 0.6 based on previous
clinical data.
Recruitment
Patients will be recruited at anxiety outpatient clinics of
specialized mental health care centers in the
Netherlands (Altrecht, GGZinGeest and UCP). Before
including patients in the study, they first undergo an in-
take interview by an experienced therapist. Eligible pa-
tients are informed about the study and are invited to a
screening and diagnostic interview (SCID) by the re-
searcher or a trained research assistant to confirm in-
and exclusion criteria. Patients receive the information
brochure and informed consent form if they are eligible
and interested in participating. Informed consent is ob-
tained by the researcher or a trained research assistant
before the start of the baseline assessment. Additionally,
participants can opt to consent to the use of their gen-
etic material in larger international databases.
Randomization and blinding
The randomization (CBD or placebo) is conducted by an
independent statistician using a computer algorithm, strati-
fying for study location and diagnosis (panic disorder with
agoraphobia or social phobia). Patients are allocated to one
of the medication groups after baseline measurements ac-
cording to the order of patients in the stratum. Investiga-
tors, research assistants, therapists and participants will be
blinded with respect to randomization. The capsules con-
taining the different medications are identical in appearance
except for filling which is either CBD or lactose (placebo).
An independent data manager can break the randomization
code in case of pregnancy, allergic reactions or any severe
inexplicable symptoms. Apart from these circumstances,
unblinding will not be done until after the last patient has
completed the last follow up measurement.
Intervention
Eight 90-min exposure sessions will be carried out by thera-
pists who are well trained in cognitive behavioral therapy
(CBT), including exposure exercises, and in the current
study protocol. Protocols in this study are based on stan-
dardized protocols of exposure with response prevention in
social phobia [39] and in panic disorder with agoraphobia
[40]. The protocols consist of therapist-assisted exposure in
vivo to fear-provoking thoughts and situations, coupled
with response prevention treatment (e.g. not leaving the
feared situation or using safety behaviors), tailored to idio-
syncratic symptoms of the patients. After every therapy ses-
sion homework is given, resulting in patients doing at least
8 exposure exercises per week.
Two hours prior to the exposure treatment sessions
the study medication is administered. Timing of admin-
istration is based on a study by Englund et al. [41], indi-
cating Tmax at 3 h 45min after administration with high
plasma levels from 2 h onwards. Therefore, taking the
medication 2 h before the start of the session results in
relatively stable CBD levels during the entire session.
The eight sessions that are part of the study protocol
are not expected to be sufficient for most patients to
achieve remission, but this allows sufficient room to in-
vestigate whether CBD strengthens therapy response
relative to placebo. After the eight sessions in the study
protocol patients can continue treatment as needed
without further administration of study medication.
Assessments
Response to treatment will be assessed at baseline (T0), at
mid-treatment (T2), post-treatment (T4) and at 3 and 6
months’ follow-up (T5 and T6 respectively). During
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treatment, a short assessment is done at each therapy ses-
sion. Table 1 provides an overview of the measures that
are used at each time point. The primary endpoint of this
study is the clinical outcome post-treatment (at assess-
ment T4). The other measurements are aimed at the time
course of the effect. The mid-treatment and per session
assessments are specifically aimed at examining the possi-
bility of a quicker and/or stronger effect of exposure with
CBD as opposed to placebo, whereas the follow up mea-
surements allow evaluation of potential long term benefi-
cial effects of CBD. Furthermore, preceding the first and
last treatment session with medication administration (T1
and T3 respectively) several secondary measures will be
used to study the mechanism underlying acute effects of
CBD. Also, blood samples from these assessments will be
used to determine CBD plasma levels.
Outcome measures
Primary outcome
The primary outcome measure is the Fear Questionnaire
(FQ; [42]) which will be administered at every time point
(T0-T6) and at every treatment session.
The FQ is a part of a standard self-report questionnaire
measuring avoidance, the complete form also includes one
specific main target phobia, a global phobia rating, and five
associated anxiety and depression symptoms (not included
in this study). The version of the FQ employed here consists
of 15 items asking about the most common phobias rating
avoidance using a nine-point scale from ‘0: would not avoid
it’ to ‘8: always avoid it’. The score reflects the level of avoid-
ance, with a total score range from 0 to 120. Three subscores
can also be derived using the sum of 5 items, concerning
Agoraphobia, Blood injury phobia and Social phobia.
Secondary outcomes
Clinical questionnaires Various secondary outcome mea-
sures are used to further explore the effect of CBD augmen-
tation on general clinical and specific disorder-related
symptoms. Baseline scores on these questionnaires will be
used to develop clinical determinants of the effect from aug-
mentation with CBD. All secondary clinical questionnaires
are administered at baseline, mid- and post-treatment and
follow up assessments.
Table 1 Overview of assessments
Measure Assessment T0 T1 T2 T3 T4 T5 T6 Treat-ments
SCID Diagnosis x
General patient characteristics Demographic information x
Clinical background Therapy history x
CTQ Childhood trauma x
AQ Autism quotient x
FQ Presence and severity phobic symptoms x x x x x x
BAI Anxiety severity x x x x x x
CGI Clinical global impression x
SUDS Degree of habituation and extinction x
BDI Depression x x x x x
BSQ Somatic symptoms x x x x x
EQ5D Quality of life x x x x x
Tic-P Loss of work and productivity plus health care costs x x x x x
SPAI Social phobia and anxiety severity x x x x x
LSAS Social anxiety severity (SOC PHOB) x x x x x
PDSS Panic disorder severity (PD + AGO) x x x x x
MI Mobility inventory (PD + AGO) x x x x x
ACQ Agoraphobia severity (PD + AGO) x x x x x
Fear conditioning task Acquisition and extinction of fear learning x x x
Blood CBD level, DNA, epigenetics x x
Questionnaires that are only assessed for a specific diagnosis are specified between brackets (panic disorder with agoraphobia = PD + AGO, social phobia = SOC
PHOB). T0 = Baseline, T1 = First medication administration, T2 = Mid treatment, T3 = Last medication administration, T4 = Post treatment, T5 = Follow up (3 months),
T6 = Follow up (6 months), Treatments = All 8 therapy sessions. SCID Structured Clinical Interview for DSM disorders axis I, CTQ Childhood Trauma Questionnaire,
AQ Autism spectrum Quotient, FQ Fear Questionnaire, BAI Beck Anxiety Inventory, CGI Clinical Global Impression, SUDS Subjective Units of Distress Scale, BDI Beck
Depression Inventory, BSQ Bodily Sensations Questionnaire, EQ5D EuroQol, Tic-P Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness, SPAI
Social Phobia and Anxiety Inventory, LSAS Liebowitz Social Anxiety Scale, PDSS Panic Disorder Severity Scale, MI Mobility Inventory, ACQ Agoraphobic
Cognitions Questionnaire
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The Beck Anxiety Inventory (BAI; [43]) is a 21-item
self-report instrument that assesses the overall severity
of anxiety. Respondents rate how much each symptom
bothered them the past week on a 4-point scale, ranging
from 0 (not at all) to 3 (severely, I could barely stand it).
The BAI is scored by summing the ratings for all the 21
symptoms to obtain a total score ranging from 0 to 63.
Whereas avoidance (measured using the FQ) is a highly
relevant clinical construct, restricting analysis to just this
aspect may overlook impact on other symptoms of anx-
iety, such as physiological changes, that may not have a
direct effect on behavior as measured by the FQ. There-
fore, we have chosen to use the BAI as most important
secondary outcome, which is why it is also administered
at every treatment session with the FQ.
The Beck Depression Inventory-II (BDI-II; [44]) is a
21-item self-report instrument that is the most widely used
to assess the presence and/or intensity of depressive symp-
toms. Similar to the BAI, symptoms are scored on a
4-point scale resulting in total scores ranging from 0 to 63.
The Body Sensations Questionnaire (BSQ [45]) is a
17-item self-report instrument assessing fear for bodily
sensations associated with autonomic arousal. Items are
rated on a 5-point scale, total scores range from 17 to 85.
The Social Phobia and Anxiety Inventory (SPAI; [46])
is used to assess specific somatic symptoms, cognitions
and behavior across a range of potentially
fear-producing situations. The original SPAI has two
subscales, Social phobia (32 items) and Agoraphobia (13
items). A shorter SPAI-18 has been developed assessing
only the Social Phobia scale [47]. In this study the
SPAI-18 is combined with the original Agoraphobia sub-
scale, resulting in 31 items. Thirteen items require separ-
ate ratings concerning either four different social
situations or physiological and cognitive questions. Mean
scores are calculated for these items based on the
7-point scale ranging from 1 (never) to 7 (always). To
obtain the score the number of items is subtracted from
the summed item scores. The maximum score for the
SPAI-18 is 108, and for the Agoraphobia scale 78.
Only during the treatment sessions the Clinical Global
Impression (CGI; [48]) and Subjective Units of Distress
(SUDS; [49]) are administered. The CGI consists of 2
items, measuring illness severity and improvement. The
items are rated on a 7-point scale by the therapist, with
the severity scale ranging from 1 (normal) to 7 (amongst
the most severely ill patients), and the improvement
scale ranging from 1 (very much improved) to 7 (very
much worse). Each component is rated separately, there
is no total score [50]. The SUDS are used during expos-
ure to measure within-session extinction. Before and
after the exposure in vivo exercise percentage of fear
and credibility of thoughts about the exercise are rated
by the patient [51].
Besides the broader clinical questionnaires,
diagnosis-specific questionnaires are only administered to
patients with the diagnosis in question. Questionnaires per-
taining to the diagnosis of panic disorder with agoraphobia:
The Panic Disorder Severity Scale (PDSS; [52]) is a
7-item clinician-administered instrument assessing se-
verity of panic disorder and monitoring treatment out-
come. Items are rated on a 5-point scale which ranges
from 0 to 4, total scores are calculated by summing the
scores for the items resulting in a range of 0 to 28.
The Mobility Inventory (MI; [53]) is a 27-item
self-report instrument for the measurement of agora-
phobic avoidance behavior in specific situations. These
situations are rated both when patients are accompanied
and when they are alone. Items are rated on a 5-point
scale which ranges from 1 (never) to 5 (always), the
score is calculated by averaging the items.
The Agoraphobic Cognitions Questionnaire (ACQ;
[45]) is a 14-item self-report instrument assessing
thought concerning negative consequences of experien-
cing anxiety. Each item is rated on a 5-point scale ran-
ging from 1 (never occurs) to 5 (always occurs), total
scores are calculated by averaging the items. Specifically,
catastrophic thoughts typically noted during exposure to
anxiety-provoking experiences are used, making it highly
relevant for the assessment of therapy success.
Questionnaire pertaining to the diagnosis of social
phobia:
The Liebowitz Social Anxiety Scale (LSAS; [54]) is a
self-report instrument with 24 items measuring both fear
and avoidance across a number of social situations. Fear
scale ratings range from 0 (no fear) to 3 (severe fear),
avoidance ratings also range from 0 to 3 and are based
on percent of time avoiding the situation (0 = never, 1 =
occasionally (10%), 2 = often (33–67%), and 3 = usually
(67–100%). The LSAS is divided in two subscales, re-
lated to performance anxiety (11 items) and social inter-
action (13 items).
All clinical questionnaires have been shown to have
adequate reliability and validity (ACQ [55], BAI [56],
BDI [57], BSQ [58], FQ [59], LSAS [60], MI [53], PDSS
[61], SPAI [47]), except for the CGI [62] which is advised
to be used in accordance with other validated question-
naires, which are used in this study.
General patient characteristics Demographic informa-
tion such as age, gender, education, employment, nation-
ality and marital status will be collected using a general
demographic questionnaire at baseline. Current use of
drugs and medication is assessed with a short question-
naire. Additional questions are asked concerning the
clinical background, e.g. treatment history, and the
Childhood Trauma Questionnaire [63] is administered.
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Experimental assessment of fear learning To explore
whether capacity for fear and extinction learning at base-
line impacts the effect of CBD, and whether treatment
with CBD has impact on improvements in extinction
learning after treatment, an experimental fear condition-
ing and extinction task will be used to assess the capacity
to acquire and extinguish conditioned fear [30]. At base-
line, this task will investigate the acute effect of CBD on
extinction learning, a second extinction phase with the
same conditioned stimuli as at baseline is administered 2
h after the first ingestion of the medication. This add-
itional fear extinction phase is administered 1 to 2 weeks
after administration of the baseline fear conditioning task.
Finally, post-treatment the same fear conditioning task
will be administered, with minor adaptations to minimize
previous learning effects (e.g. with different conditioned
stimuli). With this post-treatment task, changes in rate of
extinction due to treatment is compared between the
CBD and placebo groups.
Genetics Profiling of phobic patients based on genetic
variance will be done to examine potential factors that
have impact on the effect of exposure therapy and on
the effect of CBD augmentation. In general, we expect
more benefit of CBD augmentation for individuals with
genetic profiles associated with lack of spontaneous ex-
tinction. More specifically, for the impact on CBD aug-
mentation, genetic variance in CNR1 [20], FAAH [31,
64] and genes related to treatment response in phobic
disorders [32], will be analyzed.
Cost effectiveness The documentation of (non-)medical
costs and productivity loss will be collected to assess
cost-effectiveness of CBD-augmented psychotherapy. Both
cost effectiveness-questionnaires are administered at base-
line, mid- and post-treatment and follow up assessments.
The Treatment inventory of costs in Psychiatric pa-
tients (Tic-P [65]) is a self-report questionnaire consist-
ing of two parts, medical resource, including volume of
mental and general health care utilization (direct med-
ical costs), travel to and from health care providers
(non-medical costs), and productivity loss, generated by
absence from paid work (indirect costs). Corresponding
costs are calculated by multiplying the volumes by the
corresponding reference unit prices [66].
The EuroQol five dimensions (EQ5D [67]) is a 5-item
self-report instrument which is the most commonly used
generic health status measurement. The items have five
response categories from no problems to incapacity/ex-
treme problems. Additionally, a visual analogue scale
(VAS) is used to rate their health on a scale ranging from
0 (worst possible health) to 100 (best possible health).
Statistical analysis
Treatment augmentation
Data concerning the primary and secondary outcome
measures will be analyzed by comparing the scores on the
measurement scales using mixed modeling, with medica-
tion (CBD vs. placebo) and time (time points: baseline,
mid-treatment, post-treatment and follow-ups). Analyses
are conducted according to the intention-to-treat
principle, i.e. all patients who have completed the baseline
assessment are included in the analyses. Furthermore, also
a ‘completers only’ analysis will be done including just the
participants who have completed the treatment and par-
ticipated in all measurements (T0-T6).
Patient profiling
To determine which patient characteristics may predict add-
itional benefit of CBD augmentation, explorative multilevel
analyses with treatment success as dependent variable will be
performed, with the following independent variables (among
others); medication (CBD or placebo), diagnosis (panic dis-
order with agoraphobia or social phobia), fear learning (re-
sponse during extinction, and reduction of fear from
acquisition to extinction), cannabinoid system genetics (using
a candidate gene approach focused on CNR1 and FAAH),
prior treatment history (failed CBT, SSRI, or both), clinical
state at baseline and demographic variables (gender, age).
Fear learning
Acute effect of CBD on fear learning is analyzed with re-
tention of conditioned fear, and rate of extinction in this
re-extinction phase as outcome variables, and medica-
tion as independent variable. Impact of CBD-augmented
exposure therapy on changes in rate of extinction from
baseline between the CBD and placebo groups is exam-
ined by comparing extinction before and after treatment.
Cost effectiveness
Costs of illness and intervention is measured using re-
source utilization which will be valued with unit costs
based on standardized real cost price calculations. The
economic evaluation is primarily designed as exploratory
cost-effectiveness analyses.
Data management and dissemination
To improve data completeness we have developed a study
specific digital file to store personal information and to get
reminders for upcoming assessments and missing data,
which can be accessed by the researchers per participating
center. Actual data are not collected in this file, but stored
digitally in a database on the servers of GGZinGeest, separ-
ately from personal information of the participants. To en-
sure data quality and reliability, questionnaires are
administered online and saved digitally, together with and
data from interviews. Data from treatment sessions is
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collected and entered into the study data base and subse-
quently checked by research assistants. Data management
and monitoring is conducted by data managers from
GGZinGeest. Study conduct is reported and audited in in-
terim, with final reports to the funding agency. The proce-
dures comply with Dutch data privacy laws.
If participants wish to withdraw from the intervention,
their participation in the post-treatment and follow up
assessments are encouraged. Unless participants have
withdrawn consent for follow-up, repeated attempts are
made to contact participants. In a step-wise manner, this
will involve sending emails and calling the individual on
contact numbers provided on various days of the week
and at different times. As much information as possible
will be collected from protocol non-adherers.
Adverse events occurring after entry into the study are
recorded. Investigators will determine relatedness of an
event to the study drug based among others on temporal
relationship and the subject’s clinical course.
Any modifications to the protocol which may impact
the conduct of the study, potential benefit of the patient
or may affect patient safety, including changes of study
objectives, study design, patient population, sample sizes,
study procedures, or significant administrative aspects
will require a formal amendment to the protocol. Such
amendment will be approved by the Ethics committee
prior to implementation and information on the Trial
register website will be updated to ensure transparency.
There are no interim analyses planned. The final trial
dataset will be accessible to the researchers and data man-
agers. Results of the analyses will be published in scientific
journals and presented on scientific conferences by the re-
searchers, regardless of the outcome. A summary report of
trial results written in lay language will be sent to study par-
ticipants and other people who have expressed interest.
Discussion
Phobic disorders are among the most prevalent disorders
and have a major impact on the life of patients and society
as a whole resulting in suffering and associated costs.
Evidence-based treatments of these disorders, while effective
for a large number of patients, are not adequate for a sub-
stantial group who are not sufficiently relieved from their
anxiety symptoms. One strategy may be to boost the effect-
iveness of current treatments. Enhancing exposure therapy
with pharmacological agents that affect the neurological pro-
cesses involved in the extinction of fear is an avenue that has
been explored with augmentation using d-cycloserine, with
mixed success [68]. Since an enhancer of exposure therapy is
needed but the compounds so far have not proven to be suf-
ficiently effective, we have opted to use a new strategy using
the modulation of the endocannabinoid system. This study
will be the first clinical trial in which cannabidiol is used to
augment exposure therapy for phobic patients.
It is important to note that this study is investigator
initiated, and independent from pharmaceutical or other
industry interests. Findings will be submitted to a peer
reviewed scientific journal for publication.
This study is based on the preclinical evidence that ECS
manipulations can be used to enhance (the retention of)
fear extinction. However, acute anxiolytic effects of canna-
bidiol have also been reported. One study reported anxio-
lysis during a public speaking challenge, which resembles
the type of challenges that patients with phobia are faced
with during exposure therapy [69]. Hence, an additional
possible outcome of the study is that cannabidiol reduces
fear and anxiety acutely during the treatment sessions,
making the treatments easier to tolerate. Despite the con-
viction based on other anxiolytic treatments that anxioly-
sis during exposure reduces effectiveness [70], the
expectation is that cannabidiol may combine acute anxio-
lysis with enhanced retention of treatment effects.
A strong feature of this study is the exploratory assess-
ment of genetic, experimental and clinical differences
between patients related to extinction and subsequent
treatment response. The results of this study might give
rise to new insights into the possibility of personalized
treatment, by exploring whether this strategy is best,
specifically for patients with certain characteristics.
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